Literature DB >> 15475929

Ezrin in primary cutaneous melanoma.

Suvi Ilmonen1, Antti Vaheri, Sirpa Asko-Seljavaara, Olli Carpen.   

Abstract

Ezrin is a member of the ezrin-radixin-moesin family of proteins that link the actin-containing cytoskeleton to the plasma membrane. Ezrin is also connected to signaling molecules involved in the regulation of cell survival, proliferation and migration. Here, we examined the expression of ezrin in 95 primary cutaneous melanomas and correlated ezrin expression with conventional prognostic factors and biomarkers. From 12 patients metastatic tissue samples were also examined. In addition to ezrin staining, Mib-1 proliferation antigen, p53 and Bcl-2 were evaluated. Ezrin immunoreactivity was seen in most tumors; only 19 (20%) melanomas were negative. A total of 48 (51%) tumors had weak immunoreactivity and 28 (29%) strong immunoreactivity. The intensity of ezrin immunoreactivity was associated with tumor thickness (Breslow, P=0.0008) and with tumor invasion level (Clark, P=0.004), thicker tumors having stronger immunoreactivity. Also, there was a correlation between higher Mib-1 index in tumors and strong ezrin expression. All metastatic samples (n=12) showed positive ezrin immunoreactivity. In univariate analysis of survival, patients (n=76) with positive ezrin immunoreactivity had worse clinical disease behavior than those (n=19) without ezrin immunoreactivity, but the difference was not significant (P=0.19). In multivariate analysis of survival, the ezrin immunoreactivity was not a significant marker. The results indicate that ezrin is expressed in most primary melanomas of the skin and in all metastatic tumors. Ezrin expression correlates with tumor thickness and level of invasion suggesting an association between ezrin expression and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15475929     DOI: 10.1038/modpathol.3800300

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  29 in total

1.  Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.

Authors:  Ling Ren; Sung-Hyeok Hong; Qing-Rong Chen; Joseph Briggs; Jessica Cassavaugh; Satish Srinivasan; Michael M Lizardo; Arnulfo Mendoza; Ashley Y Xia; Narayan Avadhani; Javed Khan; Chand Khanna
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.

Authors:  Kartik Krishnan; Ben Bruce; Stephen Hewitt; Dafydd Thomas; Chand Khanna; Lee J Helman
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

3.  Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma.

Authors:  Liang Wang; Gui-Nan Lin; Xiang-Li Jiang; Yue Lu
Journal:  Tumour Biol       Date:  2011-04-06

4.  Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapy.

Authors:  Paulette Mhawech-Fauceglia; Pavel Dulguerov; Amy Beck; Marta Bonet; Abdelkarim S Allal
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

5.  Expression change of ezrin as a prognostic factor in primary osteosarcoma.

Authors:  Yao Fei Wang; Jing Nan Shen; Xian Biao Xie; Jin Wang; Gang Huang
Journal:  Med Oncol       Date:  2010-09-22       Impact factor: 3.064

6.  Ezrin expression as a prognostic marker in colorectal adenocarcinoma.

Authors:  Marcelo Patara; Erika Maria Monteiro Santos; Renata de Almeida Coudry; Fernando Augusto Soares; Fábio Oliveira Ferreira; Benedito Mauro Rossi
Journal:  Pathol Oncol Res       Date:  2011-04-05       Impact factor: 3.201

7.  Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.

Authors:  Yanlin Yu; Pingyao Zeng; Jingbo Xiong; Ziyang Liu; Shelley L Berger; Glenn Merlino
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

8.  The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells.

Authors:  Francesco Lozupone; Maurizio Perdicchio; Daria Brambilla; Martina Borghi; Stefania Meschini; Stefano Barca; Maria Lucia Marino; Mariantonia Logozzi; Cristina Federici; Elisabetta Iessi; Angelo de Milito; Stefano Fais
Journal:  EMBO Rep       Date:  2009-11-06       Impact factor: 8.807

9.  Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.

Authors:  Sébastien Salas; Catherine Bartoli; Jean-Laurent Deville; Jean Gaudart; Fréderic Fina; Arlette Calisti; Gérard Bollini; Georges Curvale; Jean-Claude Gentet; Florence Duffaud; Dominique Figarella-Branger; Corinne Bouvier
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

Review 10.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.